A aminoglycoside antibacterial derived from sisomicin.
Demonstrates in vitro synergistic activity when combined with daptomycin or ceftobiprole versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA) and against Pseudomonas aeruginosa when combined with cefepime, doripenem, imipenem or piperacillin/tazobact.
This aminoglycoside has been engineered to evade modification of aminoglycoside-modifying enzymes, and ot maintains activity in the presence of most mechanisms that lead to resistance in Enterobacteriaceae, including mutations targeted by fluoroquinolones and the production of the renal glycoside-modifying enzymes, extended spectrum beta-lactamases and carbapenemases.
Once daily plazomicin was noninferior to meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug resistant strains.